Stock Scorer

Traws Pharma, Inc. (TRAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 1M 2M 3M Q1 '21: 56K Q2 '21: 57K Q3 '21: 57K Q4 '21: 56K Q1 '22: 56K Q2 '22: 57K Q3 '22: 57K Q4 '22: 56K Q1 '23: 56K Q2 '23: 57K Q3 '23: 57K Q4 '23: 56K Q1 '24: 56K Q2 '24: 57K Q3 '24: 57K Q4 '24: 56K Q1 '25: 57K Q2 '25: 2.7M Q3 '25: 0 Q4 '25: 0 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -4M Q4 '21: -3.8M Q1 '22: -4.1M Q2 '22: -4.1M Q3 '22: -5.6M Q4 '22: -5.7M Q1 '23: -6.1M Q2 '23: -4.6M Q3 '23: -5.1M Q4 '23: -4.5M Q1 '24: -5.2M Q2 '24: -123.3M Q3 '24: -8.5M Q4 '24: -5.3M Q1 '25: -5.2M Q2 '25: -1.2M Q3 '25: -4.1M Q4 '25: -7.4M Q1 '26: -6.9M Q2 '26: -3.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -3.5M Q4 '21: -3.8M Q1 '22: -4.1M Q2 '22: -4M Q3 '22: -5.4M Q4 '22: -5.4M Q1 '23: -5.8M Q2 '23: -4.2M Q3 '23: -4.7M Q4 '23: -4.2M Q1 '24: -5M Q2 '24: -123.1M Q3 '24: -8.5M Q4 '24: -29.9M Q1 '25: 21.5M Q2 '25: -915K Q3 '25: -4M Q4 '25: -7.4M Q1 '26: -7.1M Q2 '26: -3.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-12M -8M -4M 0 4M 8M 12M Q3 '21: -4.3M Q4 '21: -4.3M Q1 '22: -4.3M Q2 '22: -4.2M Q3 '22: -3.9M Q4 '22: -3.9M Q1 '23: -4.5M Q2 '23: -4.5M Q3 '23: -4.5M Q4 '23: -4.4M Q1 '24: -4.4M Q2 '24: -9.9M Q3 '24: -11.5M Q4 '24: -4M Q1 '25: -5.4M Q2 '25: -6M Q3 '25: -4M Q4 '25: -2.8M Q1 '26: -2.6M Q2 '26: -7.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-30M -15M 0 15M 30M 45M Q3 '12: 41.5M Q1 '13: -14.2M Q2 '13: -16.1M Q3 '13: -14.4M Q4 '13: -17.2M Q1 '14: -16.2M Q2 '14: -14.2M Q3 '14: -13.2M Q4 '14: -14.3M Q4 '19: -5.4M Q3 '20: -5.8M Q4 '20: -5.5M Q4 '23: -4.4M Q3 '24: -11.5M Q4 '24: -4M Q4 '25: -2.8M Q1 '13 Q3 '13 Q1 '14 Q3 '14 Q4 '19 Q4 '20 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q1 '21: 14.6M Q2 '21: 15.8M Q3 '21: 16M Q1 '22: 20.9M Q2 '22: 20.9M Q3 '22: 20.9M Q1 '23: 21M Q2 '23: 21M Q3 '23: 840.1K Q1 '24: 841.7K Q2 '24: 1M Q3 '24: 961.5K Q1 '25: 7.2M Q2 '25: 5.8M Q3 '25: 8.8M Q1 '26: 10.6M Q2 '26: 15.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '20: -0.28 Q3 '20: -0.05 Q4 '20: -2.17 Q1 '21: -2.46 Q2 '21: -2.08 Q3 '21: -1.78 Q4 '21: -0.97 Q1 '22: -0.85 Q2 '22: -0.77 Q3 '22: -0.81 Q4 '22: -0.91 Q1 '23: -0.99 Q2 '23: -1.00 Q3 '23: -6.38 Q4 '23: -11.10 Q1 '24: -16.74 Q3 '25: -5.64 Q4 '25: 0.82 Q1 '26: -1.80 Q2 '26: -1.85 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for TRAW: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.